Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program
- PMID: 16924600
- DOI: 10.1002/pds.1302
Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program
Abstract
Background: Laboratory technicians, laboratory supervisors, decontamination/remediation workers, and environmental investigators are at increased risk for repeated occupational exposure to Bacillus anthracis. In 2002, the Advisory Committee on Immunization Practices (ACIP) recommended pre-exposure vaccination for these occupational groups.
Objectives: To determine (1) the factors that influenced an individual's decision to either accept or decline Anthrax Vaccine Adsorbed (AVA), and (2) if laboratory workers' concern about AVA safety was related to their information needs and trust in the information provided.
Methods: We conducted a decision-making survey of 404 participants at 44 Laboratory Response Network laboratories located throughout the United States. All participants were enrolled between October 2002 and December 2004, and all were eligible to receive AVA according to the 2002 ACIP recommendations. Chi-square tests and multivariate logistic regression were used in the analyses.
Results: The response rate of eligible individuals at participating laboratories was 94% (404/430). Sixty-six percent of respondents accepted and 34% declined AVA. Laboratory workers who declined AVA were more likely to rate their risk of exposure to inhalation anthrax as low (OR = 6.9; 95%CI 1.7, 28.3), report being very concerned (OR = 4.1; 95%CI 1.8, 9.3) or concerned (OR = 2.0; 95%CI 1.3, 3.1) about the safety of the vaccine, report that they did not trust the information provided in the Vaccine Information Statement (VIS) (OR = 2.3; 95%CI 1.1, 4.5), and to be enrolled in the study during 2002 (OR = 24.7; 95%CI 6.4, 95.3) or 2003 (OR = 5.0; 95%CI 2.5, 9.8), the first 2 years of the study. Furthermore, we found a significant association between a participant's level of concern about the safety of AVA and their perception that they received enough information and/or trusted the information in the VIS.
Conclusions: Low perceived necessity, concern about the safety of the vaccine, and a lack of trust in the VIS were associated with the decision of laboratory workers to decline AVA. Results of this decision-making study may be used to try to improve acceptance rates of AVA among persons considered at high risk, and may inform educational efforts for other adult vaccines.
Similar articles
-
Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network.Vaccine. 2012 Feb 27;30(10):1841-6. doi: 10.1016/j.vaccine.2011.12.128. Epub 2012 Jan 9. Vaccine. 2012. PMID: 22230591
-
An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):393-401. doi: 10.1002/pds.1085. Pharmacoepidemiol Drug Saf. 2005. PMID: 15717323
-
Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003.Arch Neurol. 2006 Jun;63(6):871-5. doi: 10.1001/archneur.63.6.871. Arch Neurol. 2006. PMID: 16769869
-
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):825-40. doi: 10.1002/pds.936. Pharmacoepidemiol Drug Saf. 2004. PMID: 15386719 Review.
-
Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature.Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):259-74. doi: 10.1002/pds.1359. Pharmacoepidemiol Drug Saf. 2007. PMID: 17245803 Review.
Cited by 6 articles
-
Measuring trust in vaccination: A systematic review.Hum Vaccin Immunother. 2018 Jul 3;14(7):1599-1609. doi: 10.1080/21645515.2018.1459252. Epub 2018 May 10. Hum Vaccin Immunother. 2018. PMID: 29617183 Free PMC article.
-
Making Common Sense of Vaccines: An Example of Discussing the Recombinant Attenuated Salmonella Vaccine with the Public.Nanoethics. 2014;8(2):179-185. doi: 10.1007/s11569-014-0198-6. Epub 2014 Jul 10. Nanoethics. 2014. PMID: 25152775 Free PMC article.
-
Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.Biosecur Bioterror. 2012 Sep;10(3):264-79. doi: 10.1089/bsp.2011.0105. Epub 2012 Jul 30. Biosecur Bioterror. 2012. PMID: 22845046 Free PMC article.
-
Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.Vaccine. 2010 Aug 23;28(37):6065-75. doi: 10.1016/j.vaccine.2010.06.089. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619377 Free PMC article.
-
The anthrax vaccine and research: reactions from postal workers and public health professionals.Biosecur Bioterror. 2008 Dec;6(4):321-33. doi: 10.1089/bsp.2007.0064. Biosecur Bioterror. 2008. PMID: 19117431 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical